Trodelvy® improves breast cancer progression-free survival, finds study
Trodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk…
Trodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk of disease progression or death in certain breast cancer patients.